Upgrade to SI Premium - Free Trial

BTIG Reaffirms Celgene (CELG) at 'Buy'; Q3 Results, Update Bolster Confidence

October 28, 2016 11:30 AM
BTIG affirms Celgene Corporation (Nasdaq: CLEG) at Buy with a price target of $138 following Q3 results and update.The firm ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst EPS View

Next Articles